TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin 100 mg (Type: EXPERIMENTAL): The Sitagliptin 100 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin 100 mg during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin 100 mg and glipizide-matched placebo.
- Placebo / Glipizide 5 mg (Type: PLACEBO_COMPARATOR): The Placebo/Glipizide 5 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin-matched placebo during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin-matched placebo 100 mg and glipizide 5 mg which was allowed to be uptitrated, in a blinded fashion, to a maximum dose of 15 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Glycosylated hemoglobin (HbA1c) 7.5%-11% at screening, and 7.0%-10.0% pre-randomization~2. FPG 7.0 mmol/L-11.0mmol/L at screening and pre-randomization~3. Body mass index (BMI) 18.5 and-35.0 kg/m2 at screening~4. Antidiabetics-naive within 2 months before screening~Exclusion Criteria:~1. Diagnosis of type 1 diabetes mellitus or secondary forms of diabetes~2. History of febrile illness within 5 days prior to dosing~3. Medical history of myocardial infarction, angina/unstable angina, coronary revascularization, stroke or transient ischemic attack~4. Any medical history or current clinical evidence of congestive heart failure, New York Heart Association (NYHA) Functional Classification, Classes II-IV~5. Episode(s) of hypoglycemia adverse events (HAE) of 'severe' intensity prior to screening; either:~   1. \>1 in the previous 3 months; or~  2. \>2 in the previous 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PB-201 50/50mg by mouth,every morning and noon for 7 days (Type: EXPERIMENTAL): None
- PB-201 100/50mg by mouth,every morning and noon for 7 days (Type: EXPERIMENTAL): None
- PB-201 100/100mg by mouth,every morning and noon for 7 days (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug Delivery Via Pressurized Metered-dose Inhaler and Valved Holding Chamber in Asthmatic Children: Determination of Delivered Dose Following Coordinated and Uncoordinated Use

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* • Asthmatic children between the ages of 5 and 8 followed at Arkansas Children's Hospital.~  * The subjects must be available to complete the study.~ * The subject's parent(s) and/or the subject's legal guardian must provide written informed consent to participate in the study.~ * The subject must provide assent when older than 7 years old.~ * The subjects should have used a pMDI VHC previously and be able to use a VHC with mouthpiece.~ * The subjects should have been prescribed fluticasone or another inhaled corticosteroid delivered via a pMDI VHC combination.~ * Clinically stable asthma.~ * Cooperative, i.e., subject should be able to follow and understand instructions.~ * The subject must satisfy the study investigator about his/her fitness to participate in the study.~Exclusion Criteria:~* Clinically significant respiratory disease in the previous 4 weeks.~* Participation in any other clinical trial in the previous 4 weeks.~* Lack of cooperation, subject cannot follow and understand instructions.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 8 Years
- Healthy Volunteers: f

Study Arms:
- Age 5-6.5 (Type: None): Group 1 will consist of 16 children aged 5-6.5 years
- Aged 6.6- 8 years (Type: None): Group 2 will consist of 16 children aged 6.6- 8 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with T2DM with inadequate glycemic control (based upon fasting glucose measurements \>=130 mg/dL and \<=250 mg/dL) on metformin monotherapy or on metformin in dual combination with other glucose lowering agents (sulphonylurea \[SU\] or a meglitinide or a dipeptidyl peptidase-4 \[DPP-4\] inhibitor) are eligible for enrollment in the study.~Exclusion Criteria:~* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy~* history of a severe hypoglycemic episode within 6 months before screening~* Has repeated (ie, 2 or more over a 1-week period) fasting plasma glucose (FPG) and/or fasting self-monitored blood glucose (SMBG) measurements \>=250 mg/dL (13.88 mmol/L) during the pre-treatment phase, despite reinforcement of diet and exercise counseling~* History of or current illness considered to be clinically significant by the investigator

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: PLACEBO_COMPARATOR): Placebo Treatment A: Form=capsule route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
- 002 (Type: EXPERIMENTAL): Canagliflozin 300mg/Placebo Treatment B: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods.
- 003 (Type: EXPERIMENTAL): Canagliflozin 300mg Treatment C: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
- 004 (Type: EXPERIMENTAL): Canagliflozin 300mg/Canagliflozin 150mg Treatment D: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1 unit=mg number=150 form=capsule route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tanezumab in Osteoarthritis of the Hip or Knee (2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Osteoarthritis of the hip or knee according to Kellgren-Lawrence x-ray grade of 2~Exclusion Criteria:~* pregnancy or intent to become pregnant~* BMI greater than 39~* other severe pain, significant cardiac, neurological or psychiatric disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: ACTIVE_COMPARATOR): None
- 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Active rheumatoid arthritis (RA) diagnosed after the age of 16~* Treatment with one the following disease modifying anti-rheumatic drug: methotrexate, sulfasalazine, hydroxychloroquine or chloroquine~* 4 or more swollen joints and 4 or more tender/painful joints (from 28 joint count)and either Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or C-Reactive Protein (CRP) blood result of 10mg/L or more~* At least one of the following: documented history of positive rheumatoid factor (blood test), current presence of rheumatoid factor (blood test), radiographic erosion within 12 months prior to study enrolment, presence of serum anti-cyclic citrullinated peptide antibodies (blood test)~Exclusion Criteria:~* Females who are pregnant or breast feeding~* Poorly controlled hypertension~* Liver disease or significant liver function test abnormalities~* Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders~* Recent or significant cardiovascular disease~* Significant active or recent infection including tuberculosis~* Previous failure to respond to a TNF alpha antagonist, anakinra or previous treatment with other biological agent~* Severe renal impairment~* Neutropenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dosing Regimen A (Type: EXPERIMENTAL): Oral Treatment
- Dosing Regimen B (Type: EXPERIMENTAL): Oral Treatment
- Dosing Regimen C (Type: PLACEBO_COMPARATOR): Oral Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MultiPoint Pacing IDE Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets current clinical indication for implantation of a cardiac resynchronization therapy system for treatment of heart failure or life-threatening ventricular tachyarrhythmia(s)~* Receiving a new CRT implant or undergoing an upgrade from an existing ICD or pacemaker implant with no prior LV lead placement~* Have the ability to provide informed consent for study participation and are willing and able to comply with the prescribed follow-up tests and schedule of evaluations~Exclusion Criteria:~* Have had a recent Cerebrovascular Accident (CVA) or Transient Ischemic Attack (TIA) within 3 months of enrollment~* Have an existing Class I recalled lead~* Have a hypersensitivity to a single 1.0mg dose of dexamethasone sodium phosphate~* Have a classification of Status 1 for cardiac transplantation or consideration for transplantation over the next 9 months~* Have permanent atrial fibrillation (AF)~* Have undergone a cardiac transplantation within 40 days of enrollment~* Have had a recent myocardial infarction, unstable angina within 40 days or cardiac revascularization within 3 months of implant.~* Are currently participating in a clinical investigation that includes an active treatment arm~* Are pregnant or planning to become pregnant during the duration of the study~* Have a life expectancy of less than 9 months due to any condition~* Are less than 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Multi-point pacing arm (Type: EXPERIMENTAL): MultiPoint Pacing
- Biventricular arm (Type: ACTIVE_COMPARATOR): Traditional Biventricular Pacing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Genicular Nerve Block in Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* juvenile idiopathic arthritis with persistent knee arthritis~* age below 16~Exclusion Criteria:~* severe knee osteoarthritis~* peripheral neuropathy,~* psoriatic arthritis,~* those under anticoagulant therapy, skin infection,~* prior knee injection in the last 3 months3~* those who have an allergy to Bupivacaine

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Active genicular nerve block group (Type: ACTIVE_COMPARATOR): group 1 will receive genicular nerve block. The injection and US examination will be done by two experienced sonographers. They were blinded to clinical data. Patients will also be blinded for the injected substance. Each point will be injected with 2 ml of Lidocaine hydrochloride 2 % (Xylocaine, Astrazeneca). The injection will be done using the 3 point technique (superior medial, superior lateral, and inferior medial genicular nerves).
- intra-articular steroid injection group (Type: OTHER): while group 2 received intra-articular triamcinolone under ultrasound guidance and through injecting the supra-patellar bursa.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Noninferiority Oral Tranexamic Acid vs Intravenous Administration in Total Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- ASA physical status 1, 2 and 3 scheduled for primary total hip arthroplasty~Exclusion Criteria:~* Renal failure with serum creatinine level higher than 1,40 mg/dL~* Thromboembolic events in last 12 months before surgery~* Pregnancy~* Congenital or acquired coagulation diseases~* History of gastric surgery that could lead to malabsorption~* Diabetic gastro-paresis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Oral Tranexamic Acid (Type: ACTIVE_COMPARATOR): 128 patients scheduled for primary total hip arthroplasty
- Intravenous Tranexamic Acid (Type: ACTIVE_COMPARATOR): 128 patients scheduled for primary total hip arthroplasty

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with moderate Rosacea (Global Severity Score of 3),~* Subjects willing to stop their current rosacea medication for at least 2 weeks~* Subjects must have an established routine of cosmetics application (e.g. must have been using the same facial foundation for at least 3 months and it is not expected to change during the study)~* Subjects must be willing to use their routine facial foundation and not change products while on study~Exclusion Criteria:~* Subjects who do not routinely wear facial foundation~* Subjects who failed to undergo a washout period of 14 days for the use of topical rosacea therapy, (for example: metronidazole, azelaic acid, sulfacetamide)~* Subjects who are unwilling to stop their current rosacea medications for 2 weeks

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Female Subjects aged 20 to 75 inclusive, with a diagnosis of moderate (Global Severity Score of 3) Rosacea

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Hodgkin's lymphoma (histologically proven)~* Clinical stage IIB (with risk factors bulky mediastinal mass and/or extranodal involvement), III, or IV~* No prior antitumor therapy~* Age 60 to 75 years~* WHO performance status 0-2~* Normal pulmonary function~* Written informed consent~Exclusion Criteria:~* The following histologies are excluded: lymphocyte predominant HD~* Leukocytes \< 2,500/microL~* Platelets \< 100,000/microL

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Cytologically confirmed acute promyelocytic leukemia (APL) or the variant form of APL~  * Previously untreated disease~ * Low- or intermediate-risk disease~    * Low-risk disease, defined as white blood cell (WBC) ≤ 10,000/mm\^3 and platelet count \> 40,000/mm\^3~   * Intermediate-risk disease, defined as WBC ≤ 10,000/mm\^3 and platelet count ≤ 40,000/mm\^3~   * WBC and platelet count confirming low- or intermediate-risk disease must be obtained within 48 hours prior to study registration unless the patient received tretinoin therapy prior to study registration in which case the WBC and platelet count must be obtained within 48 hours prior to study therapy~* PML-RARα fusion gene positive by reverse transcriptase-polymerase chain reaction (RT-PCR) assay~* No recurrent disease~* Must be registered on clinical trials SWOG-9007 and SWOG-S9910~  * Specimens must be collected prior to tretinoin therapy and may be collected after tretinoin therapy~PATIENT CHARACTERISTICS:~* Zubrod performance status 0-3~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception for ≥ 1 month prior to, during, and for 2 months after completion of study treatment~* No unstable cardiac arrhythmia or unstable angina~* No other malignancy within the past 5 years except for the following:~  * Adequately treated basal cell or squamous cell skin cancer~ * Carcinoma in situ of the cervix~ * Adequately treated stage I or II cancer (except for highly aggressive malignancies with a high rate of early relapse) currently in complete remission~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No more than 1 prior dose of intrathecal chemotherapy for acute leukemia~* No prior systemic chemotherapy, hydroxyurea, or leukapheresis for acute leukemia~  * Prior tretinoin at a dose of ≤ 45 mg/m\^2/day allowed provided it was received ≤ 5 days prior to study registration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Post-consolidation therapy arm I (Type: EXPERIMENTAL): Patients receive oral tretinoin twice daily on days 1-7, oral mercaptopurine once daily on days 1-14, and oral methotrexate on day 1. Treatment repeats every 2 weeks for up to 1 year.
- Post-consolidation therapy arm II (Type: NO_INTERVENTION): Patients receive no further chemotherapy. Patients are followed every 3 months for 1 year. (Randomization and observation arm closed as of 8/15/10)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Temporary Clamping of Drains Combined With Tranexamic Acid Reduce Blood Loss After TKA: A Prospective RCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* The patients younger than 85 years with knee osteoarthritis~Exclusion Criteria:~* The patient diagnosed secondary osteoarthritis (eg, rheumatoid arthritis, posttraumatic arthritis, gouty arthritis, postseptic arthritis)~* High-risk medical comorbid patient~* The patient who was planed for simultaneous bilateral TKAs~* The patient who had history of thromboembolic disease or bleeding disorder~* The patient who was receiving anticoagulant drug treatment~* The patient who had allergy to tranexamic acid

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): No clamp and placebo
- Group B (Type: EXPERIMENTAL): Tranexamic acid
- Group C (Type: EXPERIMENTAL): Drain clamping
- Group D (Type: EXPERIMENTAL): Drain clamping and tranexamic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete